(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 15.38% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 3.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 59.56%.
Exagen's revenue in 2025 is $55,641,000.On average, 2 Wall Street analysts forecast XGN's revenue for 2025 to be $1,149,057,892, with the lowest XGN revenue forecast at $1,136,529,223, and the highest XGN revenue forecast at $1,161,586,560.
In 2026, XGN is forecast to generate $1,331,618,491 in revenue, with the lowest revenue forecast at $1,324,459,252 and the highest revenue forecast at $1,338,777,730.